10-Q · May 13, 2026
Onconetix, Inc. reported Q1 2026 results with a significant revenue drop to $21,457, compared to $101,630 in Q1 2025. Operating losses decreased markedly from $12,570,829 to $10,225,801, reflecting improved efficiencies…
Earnings analysis · 10-Q
ONCO earnings analysis
Filed August 13, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q extract does not include current-quarter income-statement, segment, balance-sheet detail beyond selected liquidity figures, or cash-flow statements, so revenue, margins, EPS and free cash flow are not…
Read full summary
The supplied 10-Q extract does not include current-quarter income-statement, segment, balance-sheet detail beyond selected liquidity figures, or cash-flow statements, so revenue, margins, EPS and free cash flow are not reported here. Liquidity remains fragile: cash was approximately $5.9 million at June 30, 2026, while the company reported a $7.1 million six-month net loss, $4.0 million of six-month negative operating cash flow and approximately $138.3 million of accumulated deficit. A July 28, 2026 Series F financing and new ELOC provide additional capital access, but management continues to identify substantial doubt about going-concern status and material weaknesses in internal controls.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Cash Position Disclosed
Management reported approximately $5.9 million of cash and a $3.6 million working-capital surplus as of June 30, 2026. Cash was approximately $5.4 million as of August 10, 2026.
-
New Financing and ELOC Added
Subsequent to June 30, 2026, the company completed a Series F financing and entered into a new ELOC on July 28, 2026, providing additional liquidity and access to capital.
-
Internal-Control Remediation Underway
Management has initiated remediation measures for material weaknesses, including improved IT change-management procedures, stronger accounting and IT policies, enhanced review controls and improved segregation of duties.
-
No Material Legal Proceedings
The company disclosed no material legal proceedings and no unregistered equity transactions outside previously reported Form 8-K filings during the quarter ended June 30, 2026.
What to watch
-
Going-Concern and Funding Risk
The filing states there is substantial doubt about the company’s ability to continue as a going concern within 1 year following the report date. Cash was approximately $5.9 million at June 30, 2026, August 10 cash was approximately $5.4 million, and debt due within 12 months was approximately $0.2 million.
-
Nasdaq Delisting Risk Intensifies
Under a Nasdaq rule approved by the SEC on July 22, 2026, securities may be immediately suspended and delisted if market value of listed securities remains below $5 million for 30 consecutive business days. A hearing request would not stay the suspension, and any exception may not exceed 180 days.
-
Material Internal-Control Weaknesses
Disclosure controls and procedures were not effective as of June 30, 2026, due to material weaknesses involving cash-disbursement segregation, risk assessment, expense approvals, related-party transactions, accounting resources and IT general controls. The filing warns that remediation may not be sufficient to avoid future weaknesses.
-
Realbotix Termination Costs
If the Realbotix Transactions are terminated under certain circumstances, the company may owe a $500,000 termination fee plus transaction expenses capped at $500,000; a buyer-superior-proposal termination can also require an additional $1.5 million if that transaction closes.
Management's outlook
No quantitative revenue or EPS guidance was provided in the supplied 10-Q extract. Management states that substantial additional capital is needed to fund operations, complete the Realbotix Transactions and commercialize Proclarix.
Earlier filings 4
10-K · March 13, 2026
Onconetix is a commercial-stage biotech focused on commercializing Proclarix (acquired via Proteomedix) and has paused/abandoned other product efforts (ENTADFI impaired). The 10-K discloses a strained liquidity profile…
10-Q · November 13, 2025
Onconetix reported Q3 revenue of $303,651 (up $197,157 or +185.1% sequentially from Q2 2025 revenue of $106,494) with gross profit of $268,894 (gross margin 88.6%). Despite better top-line and gross-margin trends, the…
10-Q · August 14, 2025
Onconetix reported Q2 2025 revenue of $106,494 (up $4,864 or +4.8% sequentially from Q1 2025's $101,630) with gross profit of $70,503 (gross margin 66.2%). The company materially reduced quarterly net loss to $2,372,442…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.